Cybin Inc. Reports Strong Shareholder Participation in 2025 Annual Meeting
Cybin Inc. announced robust shareholder engagement with nearly 49% of outstanding shares represented at its annual meeting, demonstrating significant investor confidence in the company's late-stage neuropsychiatry treatments for major depressive disorder and generalized anxiety disorder.
Cybin Inc. (NYSE American: CYBN) (Cboe CA: CYBN) reported strong shareholder participation in its annual meeting held August 18, 2025, with 90 shareholders representing 11,264,212 common shares participating either in person or by proxy. This level of engagement accounted for 48.92% of the company's issued and outstanding common shares as of the record date, indicating substantial investor interest in the clinical-stage neuropsychiatry company's direction and progress.
The voting results matter significantly as they reflect shareholder confidence in Cybin's mission to revolutionize mental healthcare through next-generation treatments. The company is addressing the large unmet need for effective mental health treatments, particularly through its advanced pipeline of investigational compounds. Cybin's work represents a potential paradigm shift in how mental health conditions are treated, moving toward intermittent treatments that provide long-lasting results rather than daily medication regimens.
Cybin's clinical development program includes CYB003, a proprietary deuterated psilocin analog currently in Phase 3 studies for adjunctive treatment of major depressive disorder. The company is also advancing CYB004, a proprietary deuterated N, N-dimethyltryptamine molecule in Phase 2 study for generalized anxiety disorder. These late-stage developments position Cybin at the forefront of neuropsychiatry innovation, with promising proof-of-concept data supporting their potential to transform mental healthcare.
The strong shareholder turnout suggests investors recognize the importance of Cybin's research pipeline of investigational, 5-HT-receptor focused compounds. Founded in 2019, Cybin has rapidly expanded its operational presence across Canada, the United States, the United Kingdom, the Netherlands and Ireland, demonstrating the global relevance of its mental health treatment approaches. Additional information about the company's developments is available in its newsroom.
The annual meeting results come at a critical time for mental healthcare innovation, as traditional treatment options often fall short for many patients. Cybin's approach to developing novel therapeutics that provide sustained benefits from intermittent dosing could address significant limitations in current mental health treatment paradigms. The shareholder support evidenced by the meeting participation underscores the investment community's belief in Cybin's potential to deliver meaningful solutions for conditions affecting millions worldwide.